| 577 | For the management of moderate to severe opioid use disorder as a part of a complete treatment plan that includes counselling and psychosocial support in adult patients who meet the following criteria:
- The patient has been induced and is stabilized on an equivalent of 8mg to 24mg per day of transmucosal buprenorphine for a minimum of seven days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder; AND
- Each dose is administered subcutaneously in the abdominal region by a certified healthcare provider who has received instruction and training.
Recommended dose: 300mg/month for two months, followed by a maintenance dose of 100mg/month. Maintenance dose may be increased to 300mg/month only if patient does not demonstrate satisfactory clinical response.
NOTE: In clinical trials, the 300mg/month maintenance dose did not provide additional efficacy as compared to the 100mg/month dose and was associated with a higher incidence of adverse events and study discontinuations. A minimum of 26 days is required between consecutive doses. |
